Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 12/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 5/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610229 | 0.86 | ROCK1 (0.45) | TTBK1ROCK1CDC7MAP3K14CDK2 | |
| SCHEMBL16610226 | 0.84 | ROCK1 (0.43) | TTBK1ROCK1CDC7MAP3K14CDK2 | |
| SCHEMBL16610442 | 0.84 | MAP3K14 (0.46) | TTBK1ROCK1CDC7MAP3K14CDK2 | |
| SCHEMBL16610218 | 0.84 | TTBK1 (0.67) | TTBK1ROCK1CDC7MAP3K14TTBK2 | |
| SCHEMBL16610230 | 0.83 | ROCK1 (0.47) | TTBK1ROCK1CDC7MAP3K14CDK2 | |
| SCHEMBL16610256 | 0.81 | CDC7 (0.42) | TTBK1ROCK1CDC7MAP3K14CDK2 | |
| SCHEMBL16610435 | 0.81 | ROCK1 (0.44) | TTBK1ROCK1CDC7MAP3K14CDK2 | |
| SCHEMBL16610228 | 0.81 | TTBK1 (0.36) | TTBK1 | |
| SCHEMBL16610441 | 0.79 | CDC7 (0.45) | TTBK1ROCK1CDC7MAP3K14CDK2 | |
| SCHEMBL16610195 | 0.79 | TTBK1 (0.52) | TTBK1ROCK1CDC7MAP3K14TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071566-B1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-15 | — | — | EP | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| WO-2015044267-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005773-B2 | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | TTBK1 578/4885ROCK1 816/4885CDC7 620/4885 |
| US-20160257679-A1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K12 | TTBK1 558/4885ROCK1 837/4885CDC7 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.